OPM and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases

Oncodesign Precision Medicine and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases

Dijon and Strasbourg (France), January 8, 2026, at 6:00 p.m. CET, Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Ksilink, a leader in high-throughput phenotypic screening of patient-derived cell systems, method enabling direct analysis of cells from patients, to identify new therapeutic targets and molecules, today announced the launch of a new research collaboration.